tiprankstipranks
Syndax Pharmaceuticals Inc. (SNDX)
NASDAQ:SNDX
US Market
SNDX
Syndax Pharmaceuticals
RESEARCH TOOLSreports
Want to see SNDX full AI Analyst Report?

Syndax Pharmaceuticals (SNDX) Stock News & Sentiment

927 Followers
Analyst Reiterates Buy on Syndax as Commercial Momentum Builds and Clinical Data Strengthens, Maintains $40 Price Target
Premium
Ratings
Analyst Reiterates Buy on Syndax as Commercial Momentum Builds and Clinical Data Strengthens, Maintains $40 Price Target
21d ago
SNDX
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
Premium
Ratings
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
21d ago
SNDX
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push
Premium
Company Announcements
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push
3M ago
SNDX
SNDX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
3M ago
SNDX
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next
4M ago
SNDX
Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
Premium
Ratings
Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
4M ago
SNDX
Syndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
Premium
Ratings
Syndax: Strong Revuforj and Niktimvo Momentum Undervalues Commercial Trajectory and Pipeline Upside
4M ago
SNDX
More SNDX News >

SNDX News on the Web

Syndax Pharmaceuticals Stock Sinks Despite Wall Street Support
TipRanks News
Bearish
Syndax price target raised to $34 from $28 at Goldman Sachs
TipRanks News
Bullish
Syndax price target lowered to $43 from $45 at Mizuho
TipRanks News
Neutral
Jefferies Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
TipRanks News
Bullish
Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanks News
Bullish
Syndax assumed with a Buy at Jefferies
TipRanks News
Bullish
Why Syndax Pharmaceuticals Stock Is Suddenly Surging
TipRanks News
Bullish
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
The Motley Fool
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average5 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SNDX’s Media Buzz Sentiment?
Currently, no data Available
What is SNDX’s weekly average amount of articles?
In an average week, 5 articles about SNDX are published.
    What is SNDX’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    RLAYRelay Therapeutics
    GOSSGossamer Bio
    IMVTImmunovant
    ROIVRoivant Sciences
    PROKProKidney
    Showing the stocks with the most bullish news sentiment over the past week